IRIS Accounts Production v25.3.0.601 07961567 director 1.3.24 28.2.25 28.2.25 0 0 false true false false true false Ordinary shares 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh079615672024-02-29079615672025-02-28079615672024-03-012025-02-28079615672023-02-28079615672023-03-012024-02-29079615672024-02-2907961567ns15:EnglandWales2024-03-012025-02-2807961567ns14:PoundSterling2024-03-012025-02-2807961567ns10:Director12024-03-012025-02-2807961567ns10:PrivateLimitedCompanyLtd2024-03-012025-02-2807961567ns10:SmallEntities2024-03-012025-02-2807961567ns10:AuditExempt-NoAccountantsReport2024-03-012025-02-2807961567ns10:SmallCompaniesRegimeForDirectorsReport2024-03-012025-02-2807961567ns10:SmallCompaniesRegimeForAccounts2024-03-012025-02-2807961567ns10:FullAccounts2024-03-012025-02-2807961567ns10:OrdinaryShareClass12024-03-012025-02-2807961567ns10:CompanySecretary12024-03-012025-02-2807961567ns10:RegisteredOffice2024-03-012025-02-2807961567ns5:CurrentFinancialInstruments2025-02-2807961567ns5:CurrentFinancialInstruments2024-02-2907961567ns5:ShareCapital2025-02-2807961567ns5:ShareCapital2024-02-2907961567ns5:RetainedEarningsAccumulatedLosses2025-02-2807961567ns5:RetainedEarningsAccumulatedLosses2024-02-2907961567ns5:PlantMachinery2024-02-2907961567ns5:FurnitureFittings2024-02-2907961567ns5:PlantMachinery2024-03-012025-02-2807961567ns5:FurnitureFittings2024-03-012025-02-2807961567ns5:PlantMachinery2025-02-2807961567ns5:FurnitureFittings2025-02-2807961567ns5:PlantMachinery2024-02-2907961567ns5:FurnitureFittings2024-02-2907961567ns5:WithinOneYearns5:CurrentFinancialInstruments2025-02-2807961567ns5:WithinOneYearns5:CurrentFinancialInstruments2024-02-2907961567ns10:OrdinaryShareClass12025-02-28
REGISTERED NUMBER: 07961567 (England and Wales)















VANTAGE POINT MEDICAL LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 28 FEBRUARY 2025






VANTAGE POINT MEDICAL LIMITED (REGISTERED NUMBER: 07961567)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3 to 5


VANTAGE POINT MEDICAL LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 28 FEBRUARY 2025







DIRECTOR: Professor J C C Kaski-Fullone





SECRETARY: Dr M S Carpani De Kaski





REGISTERED OFFICE: 3rd Floor, Marlborough House
298 Regents Park Road
Finchley
London
N3 2SZ





REGISTERED NUMBER: 07961567 (England and Wales)





ACCOUNTANTS: Duncan & Toplis Limited
3rd Floor
Marlborough House
298 Regents Park Road
Finchley
London
N3 2SZ

VANTAGE POINT MEDICAL LIMITED (REGISTERED NUMBER: 07961567)

STATEMENT OF FINANCIAL POSITION
28 FEBRUARY 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,813 1,639

CURRENT ASSETS
Debtors 5 6,012 14,658
Cash at bank 177,120 149,000
183,132 163,658
CREDITORS
Amounts falling due within one year 6 12,479 6,581
NET CURRENT ASSETS 170,653 157,077
TOTAL ASSETS LESS CURRENT LIABILITIES 172,466 158,716

CAPITAL AND RESERVES
Called up share capital 7 100 100
Retained earnings 172,366 158,616
SHAREHOLDERS' FUNDS 172,466 158,716

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 17 September 2025 and were signed by:





Professor J C C Kaski-Fullone - Director


VANTAGE POINT MEDICAL LIMITED (REGISTERED NUMBER: 07961567)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1. STATUTORY INFORMATION

Vantage Point Medical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable for services rendered, net of discounts and value added tax. Revenue from the rendering of services is measured by reference to the stage of completion of the service transaction at the end of the reporting period provided that the outcome can be readily estimated. When the outcome cannot be readily estimated, revenue is recognised only to the extent that expenses recognised are recoverable.

Tangible fixed assets
Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Plant and machinery- 20% straight line
Fittings fixtures and equipment- 20% straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Financial instruments
Basic financial instruments are recognised at amortised cost with changes recognised in profit or loss. Derivative financial instruments are initially recorded at cost and thereafter at fair value with changes recognised in profit or loss.

Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

VANTAGE POINT MEDICAL LIMITED (REGISTERED NUMBER: 07961567)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

2. ACCOUNTING POLICIES - continued

Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2024 - NIL).

4. TANGIBLE FIXED ASSETS
Fixtures,
Plant and fittings
machinery & equipment Totals
£    £    £   
COST
At 1 March 2024 5,846 8,739 14,585
Additions 1,516 - 1,516
At 28 February 2025 7,362 8,739 16,101
DEPRECIATION
At 1 March 2024 5,846 7,100 12,946
Charge for year 303 1,039 1,342
At 28 February 2025 6,149 8,139 14,288
NET BOOK VALUE
At 28 February 2025 1,213 600 1,813
At 29 February 2024 - 1,639 1,639

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 2,400 13,200
Other debtors 3,612 1,458
6,012 14,658

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 23 18
Taxation and social security 7,307 2,599
Other creditors 5,149 3,964
12,479 6,581

VANTAGE POINT MEDICAL LIMITED (REGISTERED NUMBER: 07961567)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
100 Ordinary shares £1.00 100 100